Biologics CDMO Company in India

Fully Integrated Biologics CDMO in India Serving Worldwide

Shilpa Biologicals is a fully integrated biologics CDMO that develops and manufactures complex biologic therapeutics for partners worldwide. The company operates as a single-source biologics contract development and manufacturing organization, taking molecules from early development through to commercial supply within one connected operation. This model gives sponsors a CDMO for biologics that combines scientific depth, global standards and operational agility under one quality system. Working with one organization across the program reduces the coordination, contract and timeline overhead that comes with managing multiple specialist vendors.

Shilpa Biologicals supports:

• Global pharma companies seeking a reliable biologics CDMO partner
• Emerging biotech innovators developing novel biologics
• Mid-size sponsors that need flexible development and manufacturing
• Investors and partners evaluating biologics CDMO companies

Programs span therapy areas such as oncology and immunology, where monoclonal antibodies, recombinant proteins and antibody-drug conjugates are central to modern biologic treatment.

End-to-End Biologics Development and Manufacturing

The integrated CDMO model connects every stage of the biologic lifecycle, so process knowledge stays intact and vendor handoffs are removed. The same teams design, transfer and scale each process, which reduces comparability risk and shortens the path from development to dependable commercial supply.

The end-to-end model spans:

• Cell line and process development
• Mammalian and microbial drug substance manufacturing
• Analytical characterization and comparability
• Drug product, formulation and aseptic fill-finish
• Commercial scale-up and ongoing supply

Dedicated project management coordinates technology transfer across these stages and gives sponsors a single point of accountability for the program.

Mammalian and Microbial Drug Substance Capabilities

Drug substance manufacturing runs across two expression platforms that together cover a broad range of biologic molecules:

• Mammalian cell culture based on CHO for monoclonal antibodies and recombinant proteins
• Microbial fermentation using Pichia and E. coli for recombinant proteins including human albumin

This dual-platform capability lets Shilpa Biologicals support monoclonal antibodies, recombinant proteins, antibody-drug conjugates and biosimilar molecules. Each program is matched to the host system and process that suit its molecular profile and intended scale. Process design, scale-up and characterization stay connected across both platforms, which supports a consistent quality profile as a program grows. Biosimilars will be available commercially after relevant patent expiry.

Drug Product, Fill-Finish and Analytical Testing

Beyond drug substance, the CDMO completes the route to a finished biologic with formulation, sterile drug product and full analytical support:

• Formulation development and aseptic fill-finish for sterile injectable biologics
• An EU GMP approved fill-finish line for sponsors who need European regulatory standards
• Method development, release testing and comparability studies aligned to ICH guidelines
• Stability monitoring that protects product consistency through commercial supply

These services support process changes, technology transfer and regulatory submissions throughout a program, which keeps a molecule moving without changing partners. Comparability and stability data generated through these services support both clinical progression and post-approval changes.

Global GMP Standards and Regulatory Compliance

Quality and regulatory compliance sit at the center of the operation. Documentation follows data integrity principles that support regulatory inspections and partner audits, which prepares each program for submission in priority markets.

Certifications and standards include:

• WHO-GMP
• ICH guidelines
• PIC/S GMP
• CDSCO compliance
• EU GMP approval on the fill-finish line

Priority markets supported include the United States, European Union, Canada, Brazil and Japan. For partners evaluating biologics CDMO companies on quality and trust, these credentials provide the assurance needed to outsource high-value biologic programs with confidence.

Biologics CDMO Company in India for Global Partners

As a biologics CDMO company in India, Shilpa Biologicals combines global quality standards with the cost efficiency and operational agility of an integrated single-site operation. Biopharmaceutical contract manufacturing in India gives sponsors access to skilled scientific teams and qualified infrastructure at a structure that supports affordability without compromising regulatory rigor.

The company focuses exclusively on biologics, which keeps its teams, facilities and quality systems aligned to large-molecule development and manufacturing. From novel monoclonal antibodies and recombinant proteins to antibody-drug conjugates and recombinant human albumin, Shilpa Biologicals supports partners advancing biologic therapeutics from early development to commercial market.

Engagement models range from standalone process development, drug substance or fill-finish services to full programs that run from cell line through commercial release. Organizations comparing biologics CDMO partners for development, drug substance, drug product or commercial supply can engage Shilpa Biologicals as a fully integrated, affordable and globally compliant biologics CDMO.